Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Sacituzumab Govitecan Plus EV in Metastatic UC — Stella

Home/Urothelial Cancer/Sacituzumab Govitecan Plus EV in Metastatic UC

View on ClinicalTrials.gov

Recruiting

Back to Urothelial Cancer trials

Sacituzumab Govitecan Plus EV in Metastatic UC

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Dana Farber Cancer Institute, Boston, Massachusetts

Key details

Phase

Early testing / Safety & dosing

Sponsor

Dana-Farber Cancer Institute

Collaborators

Gilead Sciences

Enrollment target

~106 participants

Started

May 2021

Primary completion

February 2027

Age range

18 Years and older

Last updated November 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.